Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq ® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)
Condition: Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9 Interventions: Biological: RotaTeq (V260); Biological: IPV Sponsor: Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Children | China Health | Gastroenteritis | Gastroenterology | Polio | Polio Vaccine | Research | Rotavirus | Rotavirus Vaccine | Vaccines